Portolan Capital Trims Stake in United Therapeutics

Institutional investor reduces holdings in biotech company by over 40%

Mar. 14, 2026 at 9:05am

Got story updates? Submit your updates here. ›

Portolan Capital Management LLC, an institutional investor, has trimmed its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 41.2% in the third quarter, according to a recent SEC filing. The firm now owns 18,076 shares of the biotechnology company's stock, down from 30,763 shares previously.

Why it matters

United Therapeutics is a prominent biotech firm focused on developing treatments for pulmonary arterial hypertension and other life-threatening illnesses. Changes in institutional ownership can provide insights into market sentiment and potential shifts in the company's outlook.

The details

Portolan Capital Management sold 12,687 shares of United Therapeutics stock during the third quarter. The firm's remaining holdings in the company are valued at $7,578,000. Several other institutional investors and hedge funds have also adjusted their positions in United Therapeutics in recent quarters.

  • Portolan Capital Management trimmed its stake in the third quarter of 2026.

The players

Portolan Capital Management LLC

An institutional investor that has reduced its holdings in United Therapeutics Corporation.

United Therapeutics Corporation

A biotechnology company focused on developing treatments for pulmonary arterial hypertension and other life-threatening illnesses.

Got photos? Submit your photos here. ›

The takeaway

This transaction highlights the shifting landscape of institutional ownership in the biotech sector, as investors adjust their portfolios in response to market conditions and company performance. United Therapeutics' continued focus on innovation and its pipeline of treatments will be closely watched by the investment community.